Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2029-01-18
Target enrollment:
Participant gender:
Summary
To find the highest tolerable dose of dualCAR-NK19/70 (a type of cell therapy) that can be
given to patients who have B-cell lymphoma that is relapsed or refractory.